Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005377 | 0.80 | GAA (0.49) | MAPTMEN1KMT2APSMD14THRB | |
| SCHEMBL30005957 | 0.78 | MAPT (0.49) | MAPTMEN1KMT2APSMD14THRB | |
| SCHEMBL30005455 | 0.78 | TDP1 (0.52) | MAPTMEN1KMT2APSMD14THRB | |
| SCHEMBL30006561 | 0.77 | MEN1 (0.52) | MAPTMEN1KMT2APSMD14THRB | |
| SCHEMBL30005833 | 0.77 | MAPT (0.55) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL30005465 | 0.76 | ALDH1A1 (0.73) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL30005561 | 0.76 | TDP1 (0.49) | MAPTMEN1KMT2APSMD14THRB | |
| SCHEMBL30005953 | 0.76 | TDP1 (0.49) | MAPTMEN1KMT2APSMD14THRB | |
| SCHEMBL30005757 | 0.75 | MEN1 (0.51) | MAPTMEN1KMT2APSMD14THRB | |
| SCHEMBL30005802 | 0.75 | NPC1 (0.55) | MAPTMEN1KMT2APSMD14THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022220725-A1 | LPXH INHIBITORS AS ANTI-INFECTIVE AGENTS | ZAMARATSKI EDOUARD (SE) | 2022-10-20 | — | — | WO | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885MEN1 142/4885KMT2A 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.